id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-263908-4ti8l2ea	Gupta, Ritesh	Diabetes and COVID-19: evidence, current status and unanswered research questions	2020-05-13		.txt	text/plain	3693	201	46	Similarly, despite the recognition of angiotensin converting enzyme 2 (ACE2) as the receptor for severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), and the role of ACE2 in lung injury; there are conflicting results with the use of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) in these patients. There is a need to further study the natural course of COVID-19 in patients with diabetes and to understand the individual, regional and ethnic variations in disease prevalence and course. It is not known whether patients with diabetes with well-controlled blood glucose levels have an increased risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). While one study in China did not find any association of ACE inhibitor use with severity of disease, there was an increased mortality in patients with COVID-19 receiving ACE inhibitors and ARBs in another study [29, 30] .	./cache/cord-263908-4ti8l2ea.txt	./txt/cord-263908-4ti8l2ea.txt